Avadel Pharmaceuticals plc

AVDL

IE00BDGMC594

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 03/07/2024 am IST			5-day change	1st Jan Change
13.89 ^USD	-1.63%		-2.80%	-1.63%

27/06	Avadel Pharmaceuticals to Join Russell 3000 Index Monday; Shares Rise After Hours	MT
12/06	Transcript : Avadel Pharmaceuticals plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM

Avadel Pharmaceuticals plc(NasdaqGM:FLML) dropped from NASDAQ Composite Index

January 02, 2017 at 10:30 am IST

Flamel Technologies SA has been removed from NASDAQ Composite Index.

Latest news about Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Join Russell 3000 Index Monday; Shares Rise After Hours	28/06	MT
Transcript : Avadel Pharmaceuticals plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM	13/06
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	05/06	MT
Avadel Pharmaceuticals Shares New LUMRYZ (sodium Oxybate) for Extended-Release Oral Suspension Data at Sleep 2024	22/05	CI
Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors	21/05	CI
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	14/05	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	13/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	10/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	09/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	08/05	MT
Avadel Pharmaceuticals Q1 Loss Narrows	08/05	MT
Avadel Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Transcript : Avadel Pharmaceuticals plc, Q1 2024 Earnings Call, May 08, 2024	08/05
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	25/04	MT
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	23/04	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	22/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	17/04	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	16/04	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	15/04	MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	11/04	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	25/03	MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday	20/03	MT
Transcript : Avadel Pharmaceuticals plc Presents at UBS Virtual CNS Day 2024, Mar-18-2024 12:30 PM	18/03
Craig-Hallum Adjusts Avadel Pharmaceuticals' Price Target to $22 From $20, Maintains Buy Rating	05/03	MT
HC Wainwright Raises Price Target on Avadel Pharmaceuticals to $25 From $21, Maintains Buy Rating	05/03	MT

Chart Avadel Pharmaceuticals plc

Duration

Period

More charts

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Avadel Pharmaceuticals plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.89 USD

Average target price

23.65 USD

Spread / Average Target

+70.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AVADEL PHARMACEUTICALS PLC	-1.63%	1.34B
ELI LILLY AND COMPANY	+55.55%	816B
NOVO NORDISK A/S	+39.85%	634B
JOHNSON & JOHNSON	-6.83%	351B
MERCK & CO., INC.	+17.15%	323B
ABBVIE INC.	+7.09%	293B
ASTRAZENECA PLC	+13.72%	238B
ROCHE HOLDING AG	+1.19%	222B
NOVARTIS AG	+13.16%	218B
AMGEN INC.	+7.87%	167B

Other Pharmaceuticals